Keytruda, first approved in 2014, is an immunotherapy drug that stimulates the body‘s immune system to detect and kill cancer cells.
Clinicians may now use the drug, in combination with Eli Lilly’s chemotherapy drug Alimta, for previously untreated patients with advanced lung cancer.
Keytruda is already approved to treat some types of non-small cell lung cancer, melanoma and head and neck cancer, among other illnesses.
More articles on supply chain:
WHO calls for global drug price transparency
Patients barter for costly medications on Facebook
PhRMA issues new membership criteria, boots more than 20 drugmakers
